A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Body weight ≥40 kilograms * Life expectancy of at least 12 weeks * Confirmed eligible HLA-A\*02 genotype and tumor with confirmed MAGE-A4 expression * Histologically confirmed locally advanced or metastatic solid tumor malignancy that has relapsed or is refractory to established therapies * Measurable disease, according to RECIST v1.1 * Adequate hematologic and end-organ function * Resolution to Grade ≤2 of all acute, clinically significant treatment-related toxicity from prior therapy * An archival tumor tissue specimen or fresh baseline biopsy (when archival is not available) is required Exclusion Criteria: * Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 3 months after the final dose of RO7617991 or tocilizumab * Clinically significant cardiopulmonary dysfunction * Clinically significant liver disease * Poorly controlled Type 2 diabetes mellitus * Active hepatitis B or C infection * Positive test for human immunodeficiency virus (HIV) * History of allergic reactions to red meat or tick bites or known galactose-alpha-1,3-galactose (alpha-gal) hypersensitivity * Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases * Symptomatic pleural effusion, pericardial effusion, or ascites or any prior procedural intervention for pleural effusion, pericardial effusion, or ascites within 6 weeks prior to enrollment * Active or history of autoimmune disease or immune deficiency * Treatment with systemic immunosuppressive medications * Prior allogeneic stem cell or solid organ transplantation